Clinical Studies Search

Protocol Summary


Protocol No.
PSCI-20-030
Prinicipal Investigator
Drabick, Joseph
Phase
Phase III
Age Group
Adult
Scope
National
Secondary Protocol No.
20-214-29/CA045-022
Title
A Phase III, Randomized, Open-label Study of Adjuvant Immunotherapy with'Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Participants at High ?sk for Recurrence (PIVOT-12)
Objective
To compare the efficacy, as measured by recurrence-free survival (RFS) by blinded independent central review (BICR) of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIa (LN metastasis > 1 mm), Stage IIIb/c/d, or Stage IV (American Joint Committee on Cancer [AJCC] 8th edition) no evidence of disease (NED) cutaneous melanoma who are at high risk for recurrence
Applicable Disease Sites
Melanoma, Skin
Status
Open
Participating Institutions
Hershey Medical Center